New tumor injection shows promise for advanced cancers
NCT ID NCT06022029
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 21 times
Summary
This early-stage trial tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), for people with advanced solid tumors or lymphomas that have not responded to other treatments. The study aims to find the safest dose and check for side effects. About 168 adults with cancers like triple-negative breast cancer, lymphoma, or head and neck cancer are being recruited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Allegheny Health Network
COMPLETEDPittsburgh, Pennsylvania, 15224, United States
-
BRCR Global
WITHDRAWNTamarac, Florida, 33321, United States
-
California Research Institute
ACTIVE_NOT_RECRUITINGLos Angeles, California, 90027, United States
-
Cancer Care Wollongong
RECRUITINGWollongong, New South Wales, 2500, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Gabrail Cancer Center Research
COMPLETEDCanton, Ohio, 44718, United States
-
MD Anderson Cancer Center
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
-
Ohio State University
COMPLETEDColumbus, Ohio, 43210, United States
-
Princess Alexandra Hospital | Metro South Health
RECRUITINGWoolloongabba, Queensland, 4102, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Southern Oncology Clinical Research Unit
COMPLETEDBedford Park, South Australia, Australia
-
St John of God Subiaco Hospital
ACTIVE_NOT_RECRUITINGSubiaco, Western Australia, 6008, Australia
-
St Vincent's Hospital
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tasman Oncology Research
RECRUITINGSouthport, Queensland, 4215, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC Hillman Cancer Center
COMPLETEDPittsburgh, Pennsylvania, 15232, United States
-
University of Texas Southwestern Medical Center
COMPLETEDDallas, Texas, 75390, United States
-
University of the Sunshine Coast Clinical Trials
RECRUITINGBuderim, Queensland, 4556, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Virginia Cancer Specialists, PC
COMPLETEDFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.